Nephros (NEPH) Competitors $2.26 -0.04 (-1.74%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.33 +0.07 (+3.10%) As of 05/21/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. EDAP, GUTS, NSPR, FONR, SRTS, MLSS, INO, NTRB, ZYXI, and VANIShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Edap Tms (EDAP), Fractyl Health (GUTS), InspireMD (NSPR), FONAR (FONR), Sensus Healthcare (SRTS), Milestone Scientific (MLSS), Inovio Pharmaceuticals (INO), Nutriband (NTRB), Zynex (ZYXI), and Vivani Medical (VANI). These companies are all part of the "medical equipment" industry. Nephros vs. Edap Tms Fractyl Health InspireMD FONAR Sensus Healthcare Milestone Scientific Inovio Pharmaceuticals Nutriband Zynex Vivani Medical Nephros (NASDAQ:NEPH) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Does the MarketBeat Community favor NEPH or EDAP? Edap Tms received 336 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 60.38% of users gave Edap Tms an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformNephrosOutperform Votes1343.33% Underperform Votes1756.67% Edap TmsOutperform Votes34960.38% Underperform Votes22939.62% Do institutionals and insiders believe in NEPH or EDAP? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 62.7% of Edap Tms shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 0.2% of Edap Tms shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to NEPH or EDAP? In the previous week, Edap Tms had 19 more articles in the media than Nephros. MarketBeat recorded 20 mentions for Edap Tms and 1 mentions for Nephros. Edap Tms' average media sentiment score of -0.01 beat Nephros' score of -1.29 indicating that Edap Tms is being referred to more favorably in the news media. Company Overall Sentiment Nephros Negative Edap Tms Neutral Do analysts rate NEPH or EDAP? Nephros presently has a consensus target price of $5.00, indicating a potential upside of 121.24%. Edap Tms has a consensus target price of $8.50, indicating a potential upside of 388.51%. Given Edap Tms' higher possible upside, analysts clearly believe Edap Tms is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Edap Tms 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility and risk, NEPH or EDAP? Nephros has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Which has better earnings & valuation, NEPH or EDAP? Nephros has higher earnings, but lower revenue than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$15.52M1.54-$1.58M$0.0732.29Edap Tms$62.77M1.04-$22.92M-$0.62-2.81 Is NEPH or EDAP more profitable? Nephros has a net margin of -6.86% compared to Edap Tms' net margin of -34.92%. Nephros' return on equity of -11.39% beat Edap Tms' return on equity.Company Net Margins Return on Equity Return on Assets Nephros-6.86% -11.39% -8.30% Edap Tms -34.92%-44.21%-25.88% SummaryNephros beats Edap Tms on 9 of the 17 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.96M$4.50B$5.38B$8.39BDividend YieldN/A43.63%5.21%4.10%P/E Ratio-25.1129.4326.8019.71Price / Sales1.5467.72389.55117.28Price / CashN/A51.0838.2534.62Price / Book2.836.236.804.50Net Income-$1.58M$68.16M$3.23B$248.18M7 Day Performance5.61%-0.19%1.53%0.23%1 Month Performance19.58%19.19%10.05%12.39%1 Year Performance1.80%21.47%16.75%7.07% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.0399 of 5 stars$2.26-1.7%$5.00+121.2%-0.9%$23.96M$15.52M-25.1130Earnings ReportEDAPEdap Tms1.8227 of 5 stars$2.15-3.2%$8.50+295.3%-71.0%$79.77M$64.12M-3.31230Earnings ReportAnalyst RevisionGap DownGUTSFractyl Health1.6929 of 5 stars$1.71+5.6%$11.00+543.3%-74.7%$79.34M$93,000.00-0.14102Gap DownNSPRInspireMD2.2409 of 5 stars$2.58-0.8%$4.50+74.4%-4.7%$79.04M$7.01M-3.4450Gap UpFONRFONAR1.7892 of 5 stars$12.37-0.2%N/A-4.9%$76.83M$101.57M10.76480News CoverageEarnings ReportAnalyst UpgradeSRTSSensus Healthcare2.7091 of 5 stars$4.55+1.3%$13.00+185.7%-20.7%$75.05M$41.81M11.3840News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMLSSMilestone Scientific1.1423 of 5 stars$0.93-2.6%$1.25+35.1%+26.5%$72.52M$8.63M-13.2230INOInovio Pharmaceuticals3.6587 of 5 stars$1.94+7.8%$12.20+528.9%-82.0%$71.15M$217,756.00-0.49320NTRBNutriband2.1833 of 5 stars$5.83+1.9%$13.00+123.0%+9.2%$65.03M$2.14M-8.2110Positive NewsZYXIZynex3.0227 of 5 stars$2.15+3.9%$6.00+179.1%-78.5%$65.01M$172.40M14.33770Gap DownVANIVivani Medical3.1245 of 5 stars$1.03-1.0%$4.00+288.3%-36.7%$61.02MN/A-2.2920News CoverageAnalyst Forecast Related Companies and Tools Related Companies Edap Tms Competitors Fractyl Health Competitors InspireMD Competitors FONAR Competitors Sensus Healthcare Competitors Milestone Scientific Competitors Inovio Pharmaceuticals Competitors Nutriband Competitors Zynex Competitors Vivani Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NEPH Stock Free NEPH Stock Alerts